The use of population pharmacokinetic analysis incorporating pharmacogenomic data within clinical development
Milligan Peter A , O Karlsson Mats , Lynn Mcfadyen , So Miyoshi
The Keio Journal of Medicine 54 ( 1) 51
2005
Challenges and potential of optimal design in late phase clinical trials through application in Alzheimer’s disease
Sebastian Ueckert , Brian Corrigan , Andrew C. Hooker , Mats Karlsson
2014
Utvärdering av övervakningssystem i Windowsmiljö
Patrik Martin , Mats Karlsson
2010
A novel covariate search method intended for PKPD models with nonparametric parameter distributions
Mats Karlsson , Scott Marshall , Rada Savic , Paul Baverel
2011
Extension of the simplified reference tissue model, to allow different non-specific concentrations in the brain region of interest and the reference region. Application to PET with the radioligand [11C]AZ10419369 displaced by AZD3783 at the serotonin 5HT1B receptor.
Katarina Varnäs , Andrew C Hooker , Mats Karlsson , Matts Kågedal
NeuroImage
2014
Pharmacokinetic-Pharmacodynamic Modeling of VEGF, sVEGFR-2, -3 and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
Brett Houk , Michael Amantea , Peter Milligan , Mats Karlsson
2012
PKPD Modeling of Predictors for Side Effects and Overall Survival in Sunitinb Treated Patients with Gastro Intestinal Stromal Tumor
Michael Amantea , Peter Milligan , Mats Karlsson , Jonathan French
1
2012
A time-to-event model for the immunogenicity of certolizumab pegol in rheumatoid arthritis subjects
LE Friberg , H Kirby , R Oliver , G Parker
2015
A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion
Dag Nyholm , Thomas Willows , Jerker Westin , Sven Pålhagen
XVIIth WFN World Congress on Parkinson's Disease and Related Disorders , Amsterdam, Netherlands, December, 2007 13
2
2007
Optimal design of ciprofloxacin in vitro time-kill experiments
Ulrika Lustig , Andrew Hooker , Mats Karlsson , Anders Kristoffersson
2015
Impact of CYP2C8*3 on paclitaxel clearance in ovarian cancer patients
Troels Korshøj Bergmann , Werner Vach , Henrik Gréen , Mats Karlsson
Joint ECCO15/ESMO34
2009
Modelling the effect of very low calorie diet on weight and fasting plasma glucose in obese type 2 diabetic patients
Mats Karlsson , Steve Choy , Maria Kjellsson , Ellen Evbjer
2016
Effektiv projektering : En analys av informationsutbyten med fokus på prefabricerade betongelement
Mats Karlsson , Jens Holmberg
2015
Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar
Mats Karlsson , Julie Stone , Ferdous Gheyas , Junghoon Lee
Journal of Pharmacokinetics and Pharmacodynamics 42
1
2015
Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma : a population pharmacokinetic/pharmacodynamic modeling analysis
B. Agoram , R. Kantaria , P. Baverel , Mats Karlsson
Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, JUN 06-10, 2015, Barcelona, SPAIN 70 35 -35
2015
Population Pharmacokinetics of Artemether and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium Falciparum Malaria.
Thomas P.C Dorlo , Joel Tarning , Nadine Kaligirwa , Mats Karlsson
2017
Rapid innovators in emerging economies : Challenges and opportunities for Swedish firms
Solmaz Filiz Karabag , Ioana Stefan , Christian Berggren , Lars Bengtsson
University of Gävle
2016
Characterization of Anti-Drug Antibody Dynamics Using a Bivariate Mixed Hidden-Markov Model
Mats Karlsson , Siv Jönsson , Elodie L. Plan , Rocio Lledo-Garcia
2019
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Gary Maartens , Florian von Groote-Bidlingmaier , Helen McIlleron , Susan L Rosenkranz
Lancet Infectious Diseases
1
2021
Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
Ferdinand Rombout , Leon Aarons , Mats Karlsson , Anthony Man
Journal of Pharmacokinetics and Pharmacodynamics 31 ( 6) 419 -440
17
2004